Barclays PLC Sells 4,111 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Barclays PLC trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,429 shares of the company's stock after selling 4,111 shares during the quarter. Barclays PLC owned 0.18% of Krystal Biotech worth $8,213,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech in the 3rd quarter valued at approximately $40,000. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares during the period. Avanza Fonder AB acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $119,000. KBC Group NV raised its stake in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after acquiring an additional 297 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Analyst Ratings Changes

KRYS has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Finally, Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Trading Down 0.6 %

Shares of NASDAQ:KRYS traded down $1.06 during midday trading on Friday, reaching $168.06. The company had a trading volume of 171,300 shares, compared to its average volume of 296,112. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The company's 50 day moving average price is $176.37 and its 200 day moving average price is $171.57. The stock has a market cap of $4.86 billion, a P/E ratio of 56.21 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.30 earnings per share. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).